Table 3.

RRs of breast cancer in relation to energy intake, using increments of 300 kcal/d

Energy intake (kcal/d)CasesPerson-yearsRR (95% CI)
Age-adjustedMultivariate model 1*Multivariate model 2
<900266,4450.79 (0.52-1.19)0.88 (0.58-1.33)0.88 (0.58-1.33)
900-1,1998617,6050.95 (0.73-1.23)1.00 (0.77-1.30)1.00 (0.77-1.31)
1,200-1,49916328,7911.10 (0.88-1.37)1.12 (0.90-1.40)1.13 (0.90-1.40)
1,500-1,79915530,1041.01.01.0
1,800-2,09911922,0571.05 (0.83-1.33)1.03 (0.81-1.30)1.02 (0.81-1.30)
2,100-2,3999114,8981.19 (0.92-1.55)1.17 (0.90-1.52)1.17 (0.90-1.51)
2,400-2,699558,6091.26 (0.92-1.71)1.25 (0.92-1.70)1.23 (0.90-1.67)
2,700-2,999314,6831.30 (0.88-1.91)1.30 (0.88-1.91)1.29 (0.87-1.89)
3,000-3,299182,6611.33 (0.82-2.17)1.35 (0.83-2.20)1.31 (0.81-2.14)
≥3,300202,8011.41 (0.89-2.25)1.49 (0.93-2.38)1.46 (0.91-2.32)
Ptrend
    Medians of categories0.0050.0190.032
    Continuous0.0030.0310.048
  • * Multivariate model 1 adjusted for study center, race (White, Black, Hispanic, Asian, Pacific Islander, American Indian/Alaskan Native), height (continuous), family history of breast cancer (yes or no), history of benign breast disease (yes or no), age at menarche (≤11, 12-13, 14-15, ≥16 y), age at first birth (≤19, 20-24, 25-29, ≥30 y, or nulliparous), parity (0, 1, 2, 3, 4, ≥5 live births), age at menopause (<40, 40-44, 45-49, 50-54, ≥55 y), menopausal hormone therapy (never used, 1-5 y of use, 6-9 y of use, ≥10 y of use), and education (≤11 y, 12 y, or high school equivalent; post-high school; college graduate; or postgraduate).

  • Additionally adjusted for BMI (continuous) and physical activity (all categories included in questionnaire).

  • The test for trend was applied to energy as a continuous variable.